

Electronic Supplementary Material

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with *EGFR*m+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Running title: Afatinib in EGFR TKI-Naïve NSCLC: Final Analysis

Haiyan Tu^{1,a} · Jifeng Feng^{2,b} · Meiqi Shi² · Jun Zhao³ · Yuyan Wang³ · Jianhua Chang⁴ · Jialei Wang⁴ · Ying Cheng⁵ · Jing Zhu⁵ · Eng-Huat Tan⁶ · Kai Li⁷ · Yiping Zhang⁸ · Victor Lee⁹ · Cheng-Ta Yang¹⁰ · Wu-Chou Su¹¹ · David Chi-Leung Lam¹² · BJ Srinivasa¹³ · Senthil Rajappa¹⁴ · Ching-Liang Ho¹⁵ · Kwok Chi Lam¹⁶ · Yi Hu¹⁷ · Shailesh Arjun Bondarde¹⁸ · Xiaoqing Liu¹⁹ · Yahui Tian²⁰ · Zhiyi Xue²⁰ · Agnieszka Cseh²¹ · Dennis Chin-Lun Huang²² · Caicun Zhou²³ · Yi-Long Wu¹

¹ Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

² Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210029, China

³ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department 1 of Thoracic Oncology Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China

⁴ Fudan University Shanghai Cancer Center, Shanghai, 200032, China

⁵ Division of Thoracic Oncology, Jilin Province Cancer Hospital, Changchun, 130012, China

⁶ Department of Medical Oncology, National Cancer Centre, Singapore, 169610, Singapore

⁷ Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China

⁸ Zhejiang Cancer Hospital, Hangzhou, 310022, China

⁹ Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China

¹⁰ Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan

¹¹ National Cheng Kung University Hospital, Tainan, 704, Taiwan

¹² Department of Clinical Oncology, department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong

¹³ HCG Hospital, Bangalore, 560020, India

¹⁴ Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India

¹⁵ Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan

¹⁶ Prince of Wales Hospital, Shatin, New Territories, Hong Kong

¹⁷ Department of Oncology, Chinese PLA General Hospital, Beijing, 100853, China

¹⁸ Shatabdi Superspeciality Hospital, Nashik, 422005, India

¹⁹ 307th Hospital of PLA, Beijing, 100070, China

²⁰ Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

²¹ Boehringer Ingelheim International GmbH, Ingelheim 55216, Germany

²² Boehringer Ingelheim Taiwan Limited, Taipei, 104, Taiwan

²³ Shanghai Pulmonary Hospital, Tongji University, Shanghai, 200433, China

^aBoth authors contributed equally to the manuscript

Corresponding author: Yi-Long Wu, syylwu@live.cn

Electronic Supplementary Material – Fig. S1. (a) TTSP and (b) PFS in patients enrolled in China with and without afatinib dose reduction in the first 6 months of treatment; and (c) TTSP and (d) PFS in patients enrolled in China with and without brain metastases. Abbreviations: PFS, progression-free survival; TTSP, time to symptomatic progression.

